The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Preliminary results from a Phase Ib trial of AS-1763, a novel non-covalent BTKi, in CLL/MCL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the preliminary results from the ongoing Phase Ib trial (NCT05602363) of AS-1763, a novel non-covalent BTK inhibitor (BTKi), in patients with previously treated B-cell malignancies, primarily R/R chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The trial is still in the dose escalation phase, but so far, the agent appears to be safe, with no treatment-related adverse events reported, and has led to partial remissions in patients with CLL. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Honoraria: AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Other (Travel, Accommodation, Expenses): AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Research Funding: AbbVie, Cellectis, Takeda, Genentech, ADC Therapeutics, Servier, TransThera Sciences, Mingsight, Aprea Therapeutics, Medisix, Incyte, Newave, Fate Therapeutics, Dialectic Therapeutics, Novalgen, Loxo Oncology, Pfizer, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
